Abstract
The aims of our randomized, single-blind trial involving 49 patients were to study the efficacy, side effects, and tolerance of metronidazole and satranidazole in patients of amebic liver abscess. Twenty-five patients received metronidazole (800 mg TID) and 24 received satranidazole (300 mg TID with placebo at mealtime). Patients recorded side effects and tolerability through a performa. The time taken for resolution of fever and pain and the fall in abscess size was not significant. However, tolerance of satranidazole as reported by the patients was significantly better than metronidazole (P < .005). The incidence of adverse effects was significantly lower in the group given satranidazole (P < .005). The incidence of nausea and metallic taste was significantly lower in the patients given satranidazole (P < .005). Thus, despite having a similar efficacy, satranidazole showed a far lower incidence of side effects and had a significantly better tolerance than Metronidazole.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Nair MD, Nagarajan K (1983) Nitroimidazoles as chemotherapeutic agents. In: Jucker E (ed) Progress in drug research, Vol 27. Birkhauser Verlag, Basel, pp 163–252
Ray DK, Tendulkar JS, Shrivastava VB, Nagarajan K (1982) Comparative efficacy of Metronidazole and other 5-nitroimidazole, in cecal amebiasis in albino mice (Mus musculus). J Antimicrob Chemother 10:355–357
Ray DK, Shrivastava VB, Tendulkar JS, Dutta AK, Bhopale KK, Chatterjee DK, Nagarajan K (1983) Comparative studies on the amebicidal activity of known 5-nitroimidazole derivatives and CG-10213-Go in golden hamsters, Mesocricetus auratus, infected in the liver or caecum or both with trophozoites of Entamoeba histolytica. Ann Trop Med Parasitol 77:287–291
Zahoor A, Knight RC, Whitty P, Edwards DI (1986) Satranidazole: mechanism of action on DNA and structure-activity correlations. J Antimicrob Chemother 18:17–25
Powell SJ, Wilmot AJ, MacLeod I, et al. (1966) Metronidazole in amebic dysentery and amebic liver abscess. Lancet 2:1329–1331
Simjee AE, Gathiram V, Jackson TFHG, Khan BFY (1985) A comparative trial of Metronidazole v. tinidazole in treatment of amebic liver abscess. S Afr Med J 68:923–924
Bhatia S, Karnad DR, Loak J (1998) Randomized double-blind trial of Metronidazole versus secnidazole in amebic liver abscess. Ind J Gastroenterol 17:53–54
Pargal A, Rao C, Bhopale KK, Pradhan KS, Masani KB, Kaul CL (1993) Comparative pharmacokinetics and amebicidal activity of Metronidazole and Satranidazole in the golden hamsters, Mesocricetus auratus. J Antimicrob Chemother 32:483–489
Gadgil SD, Vaidya AB, Talwalkar S, Doshi B, Kulkarni RD (1984) The absence of interaction of a new anti-protozoal agent Go. 10213 Cibemone. J Assoc Physicians India 32:705–708
Acknowledgments
This study was sponsored by Alkem Laboratories. The drugs for the study and finances for investigations of the patients were provided by Alkem Laboratories, New Delhi, India.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Muzaffar, J., Madan, K., Sharma, M.P. et al. Randomized, Single-Blind, Placebo-Controlled Multicenter Trial to Compare the Efficacy and Safety of Metronidazole and Satranidazole in Patients With Amebic Liver Abscess. Dig Dis Sci 51, 2270–2273 (2006). https://doi.org/10.1007/s10620-006-9111-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10620-006-9111-7